These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 37193463)
1. An Unusual Case of Stevens-Johnson/Toxic Epidermal Necrolysis Overlap Syndrome in HER2 (Human Epidermal Growth Factor Receptor 2)-Positive Breast Cancer Patient Treated With Docetaxel. Shamloul G; Desai M; Laslett N Cureus; 2023 Apr; 15(4):e37590. PubMed ID: 37193463 [TBL] [Abstract][Full Text] [Related]
2. Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Lerch M; Mainetti C; Terziroli Beretta-Piccoli B; Harr T Clin Rev Allergy Immunol; 2018 Feb; 54(1):147-176. PubMed ID: 29188475 [TBL] [Abstract][Full Text] [Related]
3. Ophthalmic Manifestations of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis and Relation to SCORTEN. Morales ME; Purdue GF; Verity SM; Arnoldo BD; Blomquist PH Am J Ophthalmol; 2010 Oct; 150(4):505-510.e1. PubMed ID: 20619392 [TBL] [Abstract][Full Text] [Related]
4. Toxic epidermal necrolysis and Stevens-Johnson syndrome/toxic epidermal necrolysis overlap in pediatric patients with a focus on newer antiepileptic drugs: A 25-year retrospective study at a single tertiary care center. Gleghorn KL; Voigt C; Kelly B Pediatr Dermatol; 2021 Jul; 38(4):812-818. PubMed ID: 34060145 [TBL] [Abstract][Full Text] [Related]
5. Treatment of toxic epidermal necrolysis by a multidisciplinary team. A review of literature and treatment results. Papp A; Sikora S; Evans M; Song D; Kirchhof M; Miliszewski M; Dutz J Burns; 2018 Jun; 44(4):807-815. PubMed ID: 29627131 [TBL] [Abstract][Full Text] [Related]
6. Stevens Johnson syndrome-Toxic Epidermal Necrolysis Overlap induced by sulfasalazine treatment: a case report. Zizi N; Elmrahi A; Dikhaye S; Fihmi N; Alami Z Tunis Med; 2015 Jul; 93(7):413-5. PubMed ID: 26757493 [TBL] [Abstract][Full Text] [Related]
7. Stevens-Johnson syndrome and toxic epidermal necrolysis: a 10-year experience in a burns unit. Houschyar KS; Tapking C; Borrelli MR; Nietzschmann I; Puladi B; Ooms M; Rein S; Houschyar M; Duscher D; Maan ZN; Reumuth G; Branski LK; Modabber A; Kluwig D; Schmitt L; Philipp-Dormston WG; Yazdi AS; Siemers F J Wound Care; 2021 Jun; 30(6):492-496. PubMed ID: 34121430 [TBL] [Abstract][Full Text] [Related]
8. Stevens-Johnson syndrome-toxic epidermal necrolysis overlap in a patient taking quetiapine and famotidine: a case report. Su CS; Kao CL J Med Case Rep; 2024 Jul; 18(1):344. PubMed ID: 39068499 [TBL] [Abstract][Full Text] [Related]
9. Improving mortality outcomes of Stevens Johnson syndrome/toxic epidermal necrolysis: A regional burns centre experience. Nizamoglu M; Ward JA; Frew Q; Gerrish H; Martin N; Shaw A; Barnes D; Shelly O; Philp B; El-Muttardi N; Dziewulski P Burns; 2018 May; 44(3):603-611. PubMed ID: 29029855 [TBL] [Abstract][Full Text] [Related]
10. Nine years of a single referral center management of Stevens-Johnson syndrome and toxic epidermal necrolysis (Lyell's syndrome). Monteiro D; Egipto P; Barbosa J; Horta R; Amarante J; Silva P; Silva A Cutan Ocul Toxicol; 2017 Jun; 36(2):163-168. PubMed ID: 27487073 [TBL] [Abstract][Full Text] [Related]
11. Differences in Treatment of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis at Burn Centers and Nonburn Centers. Nygaard RM; Endorf FW J Burn Care Res; 2020 Sep; 41(5):945-950. PubMed ID: 32498082 [TBL] [Abstract][Full Text] [Related]
12. Toxic epidermal necrolysis and Stevens-Johnson syndrome. Harr T; French LE Orphanet J Rare Dis; 2010 Dec; 5():39. PubMed ID: 21162721 [TBL] [Abstract][Full Text] [Related]
13. The use of Biobrane Rogers AD; Blackport E; Cartotto R Burns; 2017 Nov; 43(7):1464-1472. PubMed ID: 28526303 [TBL] [Abstract][Full Text] [Related]
14. Distinguishing Stevens-Johnson syndrome/toxic epidermal necrolysis from clinical mimickers during inpatient dermatologic consultation-A retrospective chart review. Weinkle A; Pettit C; Jani A; Keller J; Lu Y; Malachowski S; Trinidad JC; Kaffenberger BH; Ergen EN; Hughey LC; Smith D; Seminario-Vidal L J Am Acad Dermatol; 2019 Sep; 81(3):749-757. PubMed ID: 31150704 [TBL] [Abstract][Full Text] [Related]
15. Photodistributed Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and proposal for a new diagnostic classification. McKinley BJ; Allen ME; Michels N Eur J Med Res; 2023 Jun; 28(1):188. PubMed ID: 37303053 [TBL] [Abstract][Full Text] [Related]
16. The nationwide epidemiological survey of Stevens-Johnson syndrome and toxic epidermal necrolysis in Japan, 2016-2018. Sunaga Y; Kurosawa M; Ochiai H; Watanabe H; Sueki H; Azukizawa H; Asada H; Watanabe Y; Yamaguchi Y; Aihara M; Mizukawa Y; Ohyama M; Hama N; Abe R; Hashizume H; Nakajima S; Nomura T; Kabashima K; Tohyama M; Takahashi H; Mieno H; Ueta M; Sotozono C; Niihara H; Morita E; Kokaze A J Dermatol Sci; 2020 Dec; 100(3):175-182. PubMed ID: 33046331 [TBL] [Abstract][Full Text] [Related]
17. Drug-related Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Review. Arora R; Pande RK; Panwar S; Gupta V Indian J Crit Care Med; 2021 May; 25(5):575-579. PubMed ID: 34177178 [TBL] [Abstract][Full Text] [Related]
18. Clinicoetiological Study of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Spectrum and the Correlation of SCORTEN with Prognosis. Kanagarajan A; Murthy AB; Moni PK; Palanivel N Indian J Dermatol; 2023; 68(1):25-33. PubMed ID: 37151260 [TBL] [Abstract][Full Text] [Related]
19. Disease severity and status in Stevens-Johnson syndrome and toxic epidermal necrolysis: Key knowledge gaps and research needs. Lehloenya RJ Front Med (Lausanne); 2022; 9():901401. PubMed ID: 36172538 [TBL] [Abstract][Full Text] [Related]
20. Carbamazepine-Induced Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Overlap Treated Successfully with Oral Cyclosporin: Case report and literature review. Al Rajaibi R; Al Rumhi T; Al Abri AM Sultan Qaboos Univ Med J; 2021 Aug; 21(3):491-494. PubMed ID: 34522420 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]